Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million

Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress

Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug

Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models

Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630

Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program

Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations

New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable

Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.

Investors Scrambled to Buy This Biotech IPO

Amgen

Mirati Therapeutics

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs

REDWOOD CITY, Calif., Feb.  18, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares of common stock, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $273.7 million, before deducting underwriting discounts, commissions and other offering expenses payable by Revolution Medicines. Shares of Revolution Medicines’ common stock began trading on the Nasdaq Global Select Market on February 13, 2020 under the ticker symbol “RVMD”.  All shares in the offering were offered by Revolution Medicines.

Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.

Revolution Medicines Enters the Market With a Bang

Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range.

Revolution Medicines shares soar 85% in trading debut after IPO priced at top end of range

News for Revolution Medicines Stock (RVMD)